BR112012016549A8 - Piperazinas como agentes antimalariais - Google Patents

Piperazinas como agentes antimalariais

Info

Publication number
BR112012016549A8
BR112012016549A8 BR112012016549A BR112012016549A BR112012016549A8 BR 112012016549 A8 BR112012016549 A8 BR 112012016549A8 BR 112012016549 A BR112012016549 A BR 112012016549A BR 112012016549 A BR112012016549 A BR 112012016549A BR 112012016549 A8 BR112012016549 A8 BR 112012016549A8
Authority
BR
Brazil
Prior art keywords
piperazines
antimalarial agents
pharmaceutical compositions
malaria
medicaments
Prior art date
Application number
BR112012016549A
Other languages
English (en)
Other versions
BR112012016549A2 (pt
Inventor
Aissaoui Hamed
Boss Christoph
Corminboeuf Olivier
Heidmann Bibia
Siegrist Romain
Original Assignee
Actelion Pharmaceuticals Ltd
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd, Idorsia Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of BR112012016549A2 publication Critical patent/BR112012016549A2/pt
Publication of BR112012016549A8 publication Critical patent/BR112012016549A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

PIPERAZINAS COMO AGENTES ANTIMALARIAIS. A invenção refere-se aos derivados de piperazina de Fórmula I e a sua utilização como princípios ativos na preparação de composições farmacêuticas. A invenção também diz respeito aos aspectos relacionados incluindo composições farmacêuticas contendo um ou mais desses compostos e seu uso como medicamentos para o tratamento ou prevenção de infecções por protozoários, tal como, especialmente, malária.
BR112012016549A 2010-01-05 2011-01-04 Piperazinas como agentes antimalariais BR112012016549A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2010050022 2010-01-05
IB2010052045 2010-05-10
PCT/IB2011/050009 WO2011083413A1 (en) 2010-01-05 2011-01-04 Piperazines as antimalarial agents

Publications (2)

Publication Number Publication Date
BR112012016549A2 BR112012016549A2 (pt) 2016-04-19
BR112012016549A8 true BR112012016549A8 (pt) 2017-12-26

Family

ID=43706300

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012016549A BR112012016549A8 (pt) 2010-01-05 2011-01-04 Piperazinas como agentes antimalariais

Country Status (27)

Country Link
EP (1) EP2521715B1 (pt)
JP (1) JP5165166B1 (pt)
KR (1) KR101455484B1 (pt)
CN (1) CN102666488B (pt)
AR (1) AR079831A1 (pt)
AU (1) AU2011204436B2 (pt)
BR (1) BR112012016549A8 (pt)
CA (1) CA2783882C (pt)
CL (1) CL2012001641A1 (pt)
CY (1) CY1115600T1 (pt)
DK (1) DK2521715T3 (pt)
ES (1) ES2523739T3 (pt)
HK (1) HK1178529A1 (pt)
HR (1) HRP20140890T1 (pt)
IL (1) IL220698A (pt)
MA (1) MA33979B1 (pt)
MX (1) MX2012007172A (pt)
MY (1) MY160904A (pt)
NZ (1) NZ601607A (pt)
PL (1) PL2521715T3 (pt)
PT (1) PT2521715E (pt)
RU (1) RU2555706C2 (pt)
SG (1) SG181462A1 (pt)
SI (1) SI2521715T1 (pt)
TW (1) TWI402267B (pt)
WO (1) WO2011083413A1 (pt)
ZA (1) ZA201205879B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013018069A1 (en) 2011-08-04 2013-02-07 Actelion Pharmaceuticals Ltd Combination of antimalarial agents
WO2014072903A1 (en) * 2012-11-06 2014-05-15 Actelion Pharmaceuticals Ltd Novel aminomethyl-phenol derivatives as antimalarial agents
CA2901920A1 (en) * 2013-03-15 2014-09-18 Actelion Pharmaceuticals Ltd Novel acrylamide derivatives as antimalarial agents
EP4058147A4 (en) * 2020-01-21 2024-01-10 Eisai R&D Management Co., Ltd. NOVEL ANTIMALARIAL AGENT CONTAINING A HETEROCYCLIC COMPOUND

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9910079D0 (en) 1999-05-01 1999-06-30 Smithkline Beecham Plc Novel compounds
DE10008522A1 (de) * 2000-02-24 2001-09-06 Hassan Jomaa Verwendung von 2-PHenylendiaminderivaten zur Behandlung von Infektionen
KR20020084273A (ko) * 2000-03-31 2002-11-04 화이자 프로덕츠 인코포레이티드 신규한 피페라진 유도체
TWI382976B (zh) * 2005-10-21 2013-01-21 Actelion Pharmaceuticals Ltd 作為抗瘧疾劑之新穎哌
CN101544630B (zh) * 2009-05-13 2013-03-13 中国科学院广州生物医药与健康研究院 羟基化茚地那韦的制备方法

Also Published As

Publication number Publication date
TWI402267B (zh) 2013-07-21
RU2555706C2 (ru) 2015-07-10
AR079831A1 (es) 2012-02-22
EP2521715B1 (en) 2014-06-25
MY160904A (en) 2017-03-31
AU2011204436B2 (en) 2016-05-19
ZA201205879B (en) 2015-04-29
AU2011204436A1 (en) 2012-08-23
PL2521715T3 (pl) 2014-11-28
SI2521715T1 (sl) 2014-10-30
MA33979B1 (fr) 2013-02-01
HRP20140890T1 (hr) 2014-11-07
NZ601607A (en) 2014-06-27
PT2521715E (pt) 2014-09-02
CN102666488A (zh) 2012-09-12
IL220698A (en) 2015-09-24
KR20120111740A (ko) 2012-10-10
KR101455484B1 (ko) 2014-10-27
BR112012016549A2 (pt) 2016-04-19
CY1115600T1 (el) 2017-01-04
JP2013516453A (ja) 2013-05-13
TW201139416A (en) 2011-11-16
CL2012001641A1 (es) 2012-12-07
CN102666488B (zh) 2015-04-22
CA2783882A1 (en) 2011-07-14
CA2783882C (en) 2017-11-28
DK2521715T3 (da) 2014-08-11
JP5165166B1 (ja) 2013-03-21
WO2011083413A1 (en) 2011-07-14
HK1178529A1 (en) 2013-09-13
EP2521715A1 (en) 2012-11-14
RU2012133265A (ru) 2014-02-20
SG181462A1 (en) 2012-07-30
MX2012007172A (es) 2012-07-03
ES2523739T3 (es) 2014-12-01

Similar Documents

Publication Publication Date Title
AR117001A2 (es) Formulación de premezcla de dexmedetomidina
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
BR112017002811A2 (pt) compostos de pirrolopirimidina usados como agonista de tlr7
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
BR112015020242A2 (pt) sulfamoil-arilamidas e seu uso como medicamentos para o tratamento da hepatite b
BR112015022674A2 (pt) inibidores de bromodomínio
BR112012031561A2 (pt) morfolino pirimidinas e seu uso em terapia.
TR201904614T4 (tr) Novel pyrazole derivative.
TW200800931A (en) Novel piperazines as antimalarial agents
UA124922C2 (uk) Модулятори ядерного транспорту та їх застосування
BR112014030173A8 (pt) Composto derivado de benzimidazol-prolina, e, composição farmacêutica
MX345238B (es) (aralquilamino y heteroarilalquilamino alfa-substituidos)pirimidin ilo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas.
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
MX2022013612A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
BR112014016233A8 (pt) inibidores de bromodomínio
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
BR112014022214A2 (pt) fenólicos antibacterianos
BR112015017331A2 (pt) compostos químicos
MX2012008328A (es) Derivados de pirazina.
EA201890532A1 (ru) Новые аннелированные бензамиды
BR112018010107A2 (pt) composição farmacêutica para o tratamento ou prevenção de nash
BR112018001035A2 (pt) compostos de fenoxiacetamidas aneladas, sal farmaceuticamente aceitável, seu método de síntese, combinação de medicamento e uso dos mesmos
BR112012016549A8 (pt) Piperazinas como agentes antimalariais
EA201300857A1 (ru) Пиразолы в качестве антагонистов crth2
EA201490573A1 (ru) Соединение бензотиазолона

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: ACTELION PHARMACEUTICALS LTD (CH)

B25C Requirement related to requested transfer of rights

Owner name: ACTELION PHARMACEUTICALS LTD (CH)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]